<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007904</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1100</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>05-00-23</secondary_id>
    <secondary_id>NCI-G00-1877</secondary_id>
    <secondary_id>CWRU1100</secondary_id>
    <secondary_id>NCI-2010-01068</secondary_id>
    <nct_id>NCT00007904</nct_id>
  </id_info>
  <brief_title>Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes</brief_title>
  <official_title>A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Colony-stimulating factors such as filgrastim may increase the&#xD;
      number of immune cells found in bone marrow or peripheral blood and may help a person's&#xD;
      immune system recover from the side effects of chemotherapy. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with filgrastim and radiation therapy works in treating patients with stage II or stage IIIA&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of administering adjuvant paclitaxel, dose-intensive&#xD;
           cyclophosphamide, and filgrastim (G-CSF), followed by doxorubicin and then radiotherapy&#xD;
           in patients with stage II or IIIA breast cancer involving &gt; 4 lymph nodes.&#xD;
&#xD;
        -  Determine the incidence of febrile neutropenia in these patients during the first course&#xD;
           of therapy.&#xD;
&#xD;
        -  Compare the incidence of febrile neutropenia and duration of neutropenia in patients&#xD;
           treated with this regimen with that seen in patients treated on protocol CWRU-4194.&#xD;
&#xD;
        -  Determine the disease-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate the quality of life of these patients.&#xD;
&#xD;
        -  Correlate HER-2/neu overexpression with disease-free and overall survival in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on&#xD;
      days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and&#xD;
      continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3&#xD;
      courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21&#xD;
      days for 4 courses.&#xD;
&#xD;
      Patients with hormone receptor positive disease also receive oral tamoxifen daily for 5 years&#xD;
      beginning at the completion of chemotherapy.&#xD;
&#xD;
      Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5&#xD;
      days a week for 6-7 weeks.&#xD;
&#xD;
      Quality of life is assessed days 1 and 4 of the first course of chemotherapy, day 1 of the&#xD;
      second course, the last day of the final course, and at 6 months after the completion of&#xD;
      treatment.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of administering continuous infusion paclitaxel with dose intense cyclophosphamide</measure>
    <time_frame>9 weeks</time_frame>
    <description>Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3 given concurrently with cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3. Patients will be observed in the outpatient treatment area during the first 2 hours of the paclitaxel infusion for allergic reactions. Epinephrine, hydrocortisone, and IV antihistamine will be available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the incidence of febrile neutropenia with the first cycle of therapy.</measure>
    <time_frame>3 weeks</time_frame>
    <description>A specific objective of this trial is to estimate the incidence of febrile neutropenia. The observed incidence of febrile neutropenia with the first cycle of cyclophosphamide and paclitaxel, as well as the observed number of days of grade ¾ neutropenia during the first treatment cycle, will be reported along with 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine days of neutrophil counts below 500/uL on this regimen during the first treatment cycle.</measure>
    <time_frame>after 1st cycle (3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate dose delays and dose reductions of this regimen.</measure>
    <time_frame>at 7 cycles (21 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine disease-free and overall survival of this regimen.</measure>
    <time_frame>5 yrs after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Quality of life will be assessed using the FACT-B instrument. Quality of life will be assessed at the following timepoints: Cycle 1 day 1, Cycle 1 day 4, Cycle 2 day 1, on the final day of adriamycin, and 6 months after treatment is completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Her2/neu overexpression with disease-free and overall survival</measure>
    <time_frame>5 yrs after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC &gt; 10,000/uL x1 day after the nadir cycles 1-3.</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
    <other_name>G-CSF, Neupogen®</other_name>
    <other_name>recominant-methionyl human granulocyte-colony stimulating factor</other_name>
    <other_name>granulocyte colony stimulating factor</other_name>
    <other_name>r-methHuG-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>CTX</other_name>
    <other_name>CPM</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Patients then receive doxorubicin IV on day 1.</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.</description>
    <arm_group_label>Arm A: Combination Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage II or IIIA breast cancer&#xD;
&#xD;
               -  At least 5 axillary lymph nodes&#xD;
&#xD;
               -  No T4 or N3 disease&#xD;
&#xD;
          -  No distant metastases by CT scan of the chest, abdomen, and pelvis; bone scan; and&#xD;
             bone marrow evaluation&#xD;
&#xD;
          -  No more than 8 weeks since prior lumpectomy or mastectomy with axillary node&#xD;
             dissection&#xD;
&#xD;
               -  Negative surgical margins&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Hormone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No poorly controlled ischemic heart disease or congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe chronic obstructive or restrictive pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe diabetes mellitus&#xD;
&#xD;
          -  No other severe concurrent medical or psychiatric illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within past 5 years except curatively treated ductal carcinoma in&#xD;
             situ, lobular carcinoma in situ, or breast cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda W. Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-LUICC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH-Chagrin Highlands</name>
      <address>
        <city>Orange Village</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/results?term=cwru1100</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

